This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles…
molecule
1 year ago ●
1 min read
The AstraZeneca oral RORgt inverse agonist, AZD0284, is an inverse agonist of the nuclear receptor RORC2 (RORγt). Reviewer Chris Gampe says, “targeting the…
molecule
1 year ago ●
1 min read
The Merck KGaA MCT4 chemical probe, “compound 18n”, is a novel inhibitor of the monocarboxylate transporter MCT4. Large quantities of lactic…
molecule
1 year ago ●
1 min read
1. The H3 Biomedicine RNA splicing modulator, H3B-8800, targets the spliceosome SF3b complex containing either wild-type (WT) or mutant SF3B1.…
molecule
2 years ago ●
1 min read
2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK…
molecule
2 years ago ●
1 min read
3. The Revolution Medicines selective mTORC1 complex inhibitor, RMC-4529, is a bi-steric inhibitor that has a rapamycin-derived, FKBP12-recruiting allosteric mTOR…
molecule
2 years ago ●
1 min read
Load More
